Novel design of nonpeptide AVP V2 receptor agonists: Structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine as a template

Journal of Medicinal Chemistry

Volumn 43, Issue 23, 2000, Pages 4388-4397

  Kondo, K ^a   Ogawa, H ^a   Shinohara, T ^a   Kurimura, M ^a   Tanada, Y ^a   Kan, K ^a   Yamashita, H ^a   Nakamura, S ^a   Hirano, T ^a   Yamamura, Y ^a   Mori, T ^a   Tominaga, M ^a   Itai, A ^a,b  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^b Inst of Medicinal Molecular Design   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

(1,2,3,4 TETRAHYDRO 1H 1 BENZAZEPIN 1 YL) 2 CHLORO 4 (3 METHYLPYRAZOL 1 YL)BENZAMIDE; (1,2,3,4 TETRAHYDRO 1H 1 BENZAZEPIN 1 YL) 2 CHLORO 4 (3 METHYLPYRROLIDIN 1 YL)BENZAMIDE; (1,2,3,4 TETRAHYDRO 1H 1 BENZAZEPIN 1 YL) 2 CHLORO 4 (N,N PROPYLAMINO)BENZAMIDE; (1,2,3,4 TETRAHYDRO 1H 1 BENZAZEPIN 1 YL) 2 CHLORO 4 (PYRROLIDIN 1 YL)BENZAMIDE; (1,2,3,4 TETRAHYDRO 1H 1 BENZAZEPIN 1 YL) 4 (PYRROL 1 YL)BENZAMIDE; 1 (4 AMINOBENZOYL) 2,3,4,5 TETRAHYDRO 1H 1 BENZAZEPINE; ANILINE DERIVATIVE; ARGIPRESSIN DERIVATIVE; UNCLASSIFIED DRUG; VASOPRESSIN V2 RECEPTOR;

ANTIDIURESIS; ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG RESEARCH; DRUG STRUCTURE; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; ARGININE VASOPRESSIN; BENZAZEPINES; CYCLIC AMP; DIURESIS; DRUG DESIGN; FEMALE; HELA CELLS; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; RADIOLIGAND ASSAY; RATS; RECEPTORS, VASOPRESSIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034676327     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm000108p     Document Type: Article

References (49)

1. Vascular smooth muscle and neurohypophyseal hormones
2. Characterization of human liver vasopressin receptor. Profound differences between human and rat vasopressin-receptor-mediated responses suggest only a minor role for vasopressin in regulating human hepatic function
3. 1a type
4. Vasopressin and angiotensin II receptors in rat aortic smooth muscle cells in culture
5. Characterization of human platelet vasopressin receptors
6. 8-vasopressin binding to rat kidney and brain tissue
7. SK&F 105494 is a potent antidiuretic hormone antagonist in the rhesus monkey (Macaca mulatto)
8. SK&F 105494: A potent antidiuretic hormone antagonist devoid of partial agonist activity in dogs
9. Vasopressin receptor antagonism in rhesus monkey and man: Stereochemical requirements
10. From vasopressin antagonist to agonist: A saga of surprise!
11. 1 receptor antagonist
12. 1 antagonists. A novel series of 1-(1-substituted 4-piperidyl)-3,4-dihydro-2(1H)-quinolinone
13. 1a antagonists: 1-(1-multi-substituted benzoyl 4-piperidyl)-3,4-dihydro-2(1H)-quinolinones
14. 1 receptor of rat, rhesus and human tissues
15. 1 vasopressin receptors
16. 1a receptors
17. 1a antagonist, to rat and human liver membranes
18. Characterization of rodent liver and kidney AVP receptors: Pharmacologic evidence for species differences
19. Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor
20. 1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4-yl)-4H-3,1 -benzoxazin-2(1H)-one (L-371,257): A new, orally bioavailable, non-peptide oxytocin antagonist
21. 2 receptor antagonist
22. 2 receptor antagonists: A novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds
23. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-3260) in men
24. Aquaretic effect of a potent, orally active, nonpeptide V2 antagonist in men
25. 1a vasopressin receptor
26. Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor
27. Molecular cloning of the receptor for human antidiuretic hormone
28. 1b vasopressin receptor
29. Structure and expression of a human oxytocin receptor
30. Identification of agonist binding sites of vasopressin and oxytocin receptors
31. Molecular neurobiology and pharmacology of the vasopressin/oxytocin receptor family
32. 2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats
33. 2 receptor antagonist
34. 4-(Heteroarylthio)-2-biphenyltetrazoles as nonpeptide angiotensin II antagonists
35. Identification of peptide binding residues in the extracellular domains of the AT1 receptor
36. Structural model of antagonist and agonist binding to the angiotensin II, AT1 subtype, G protein coupled receptor
37. Differential structural requirements for specific binding of nonpeptide and peptide antagonists to the AT1 angiotensin receptor. Identification of amino acid residues that determine binding of the antihypertensive drug Iosartan
38. Synthesis and structure-activity relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles
39. Dual agonistic and antagonistic property of nonpeptide angiotensin AT1 ligands: Susceptibility to receptor mutations
40. Agonist-antagonist interactions at angiotensin receptors: Application of a two-state receptor model
41. Non-peptide angiotensin agonist. Functional and molecular interaction with the AT1 receptor
42. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist 'trigger'
43. 3-[2-(N-Phenyl-acetamide)]-1,5-benzodiazepines: Orally active, binding selective CCK-A agonists
44. Preparation of cis- and trans-2,5-dimethoxy-2-(acetamidomethyl)-2,5-dihydrofuran, of cis- and trans-dimethoxy-2-(acetamidomethoxy)-tetrahydrofuran, and 1-phenyl-2-(acetamidomethyl)pyrrole
45. The preparation of pyrroles from furans
46. Substituent effect of pyrrolidino and piperidino groups in benzoic acids and nitrobenzenes
47. 2-agonist, OPC-51803, in cells transfected human vasopressin receptor subtypes